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unitAbstract Background: Platelets have been increasingly recognized as an important component of
innate and adaptive immunity. Platelet response in antimicrobial host defense is similar, in many
ways, to the leukocyte response: both cell types contain antimicrobial peptides that act against a
broad range of pathogens.
Objective: The aim of this study was to detect whether platelet count could be used as a marker
for severity of community acquired pneumonia or not.
Subjects and methods: The study included 40 cases of community acquired pneumonia admitted at
Chest Department and Respiratory ICU at Ain Shams University Hospital, as well as, Chest Depart-
ment and Respiratory ICU at Ain ShamsUniversity Specialized Hospital. All cases were subjected to
the following: full history taking, thorough clinical examination including general and local examina-
tion, arterial blood gases, electrocardiography, radiological work up, routine laboratory investiga-
tions including compete blood picture and CURB-65 score as a marker for severity of pneumonia.
Results: The results showed that there was a signiﬁcant relation between the occurrence of respi-
ratory complications and both thrombocytopenia and thrombocytosis. Also, there was a signiﬁcant
relation between both thrombocytopenia and thrombocytosis and the CURB-65 score as a score
for severity of CAP. There was a signiﬁcant relation between both thrombocytopenia and thrombo-
cytosis and mortality among the patients with CAP. Finally, platelet count is considered better pos-
itive than a negative predictor value to the outcome.
Conclusion: A better understanding of the role of platelets in the outcomes of patients with com-
munity acquired pneumonia may generate new prognostic and therapeutic modalities for patients
with severe disease.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Platelets have been increasingly recognized as an important
component of innate and adaptive immunity. Platelet response
in antimicrobial host defense is similar, in many ways, to therculosis.
500 A.A. ElMaraghy et al.leukocyte response: both cell types contain antimicrobial
peptides that act against a broad range of pathogens. After
platelets and neutrophils are activated, they accumulate at
the site of infection to produce direct contact between their
antimicrobial peptides and invading bacteria. Leukocytes need
to phagocytize bacteria to achieve interaction with intracellu-
lar peptides; platelets can also internalize microorganisms into
phagosome-like vacuoles, enhancing pathogen clearance.
Antimicrobial peptides from both cells exert a rapid, potent,
and direct antimicrobial effect that contributes to limiting
the infection [1].
Clinicians have always evaluated the degree of leucocytosis
in patients with pneumonia as an indication of systemic
inﬂammatory response and severity of disease. Thrombocy-
topenia is also a recognized marker of poor outcomes in
patients with pneumonia due to the association of low platelet
counts with disseminated intravascular coagulation and severe
sepsis. Abnormalities in the coagulation system can be due to
low as well as high platelet count. However, the association
between thrombocytosis and clinical outcomes in adult
patients with community-acquired pneumonia (CAP) has not
been investigated [2].
Considering that platelets play a crucial role in antimicro-
bial host defenses and the coagulate system, it is hypothesized
that an abnormal platelet count may be an important marker
to assess severity of disease in patients with CAP [3,4].
Subjects and methods
This was a prospective study of the relation between platelet
count abnormality and the severity and outcome of
community-acquired pneumonia cases. The study included
40 cases of CAP admitted at the Chest Department and Respi-
ratory ICU at Ain Shams University Hospital, as well as,
Chest Department and Respiratory ICU at Ain Shams Univer-
sity Specialized Hospital.Table 1 Distribution of the studied patients as regards the
general data.
Variables Number %
Gender
Male 30 75
Female 10 25
Site
Lobar 32 80
Multilobar 8 20
Respiratory failure
Non 8 20
Type 1 12 30
Type 2 20 50
Outcome
Alive 17 42.5
Died 23 57.5
Complications
No 19 47.5
Respiratory 12 30.0
Non respiratory 7 17.5
Both 2 5.0
Length of hospital stay 11.5 ± 5 3–25
Age 60 ± 17 17–84All cases were subjected to the following:
1. Full history taking.
2. Thorough clinical examination including general and local
examination.
3. Arterial blood gases.
4. Electrocardiography.
5. Radiological work up (conventional CXR, CT scan and/or
chest ultrasound).
6. Routine laboratory investigations including compete blood
picture.
7. CURB-65 score tool.
CURB-65 Mortality Prediction Tool for Patients with
Community-Acquired Pneumonia [5].
Prognostic variables*
Confusion
Blood urea nitrogen level >20 mg per dL (7.14 mmol per L)
Respiratory rate P30 breaths per minute
Blood pressure (systolic <90 mmHg or diastolic 660 mmHg)
Age P65 years
Score Inpatient vs. outpatient 30-day mortality (%)0 or 1 point Treat as outpatient 0.7–2.12 points Treat as inpatient 9.2P3 points Treat in intensive care unit 15–40
*Assign 1 point for each variableStudy definitions
CAP is deﬁned as the presence of a new pulmonary inﬁl-
trate on chest radiograph at the time of hospitalization
associated with at least one of the following: (1) new or
increased cough, (2) an abnormal temperature (<35.6 C
or > 37.8 C), (3) an abnormal serum leukocyte count
(leucocytosis, left shift, or leucopenia deﬁned by local labo-
ratory values). CAP severity was measured using CURB-65
scoring tool.
Hypotension is deﬁned as a systolic blood pressure
<90 mmHg or diastolic blood pressure <60 mmHg.
Alteration of gas exchange is deﬁned as Pa O2 <60 mmHg
or Pa O2/FIO 2 < 300 or O2 saturation <90%.
Thrombocytopenia and thrombocytosis are deﬁned as pla-
telet counts <150,000/L or >400,000/L, respectively.
Patients with immunosuppression, neoplasms, active TB or
hematologic diseases were excluded.
Statistical methodology
Analysis of data was done by IBM computer using SPSS (sta-
tistical program for social science version 16) as follows:
 Description of quantitative variables as mean, SD and
range.
 Description of qualitative variables as number and
percentage.
 Fisher exact test was used instead of chi-square test when
one expected cell or more less than or equal 5.
Table 3 Correlation between mean of platelet count versus
age and length of hospital stay.
Variables Platelet count Signiﬁcance
r P
Age 0.14 0.56 NS
Length of hospital stay 0.009 0.54 NS
Platelet count as a marker for severity of community acquired pneumonia 501Validity parameters from ROC (receiver operator characteristic
curve)
 Sensitivity = true ve +/true + ve + false –ve.
 = ability of the test to detect + ve cases.
 Speciﬁcity = true -ve/true-ve + false + ve.
 = ability of the test to exclude negative cases.
 PPV (positive predictive value) = true+/true + ve ± false
+ ve.
 =% of true + ve cases to all positive.
 NPV= true-/true-ve + false –ve.
 =% of the true –ve to all negative cases.
 Accuracy = true + ve + true-ve/grand total [6].
P value > 0.05 insigniﬁcant.
P 6 0.05 signiﬁcant.
P< 0.01 highly signiﬁcant.
Results
Table 1 shows that 75% of the enrolled patients were males
and 25% were females, the age ranged from 17 to 84 years with
a mean of 60 ± 17 years, the length of hospital stay ranged
from 3 to 25 days with a mean of 11.5 ± 5 days, 80% of the
patients presented with lobar consolidation while the other
20% presented by multilobar consolidation, 50% of the
included patients had type II respiratory failure, 30% had type
I respiratory failure, while only 20% of the patients did not
have respiratory failure, 47.5% of the patients did not develop
any complications, 30% developed respiratory complications,
17.5% developed non-respiratory complications and 5%
developed both respiratory and non-respiratory complications,
and ﬁnally, 42.5% of the patients survived while 57.5% of
them died.
Table 2 shows that there was no signiﬁcant statistical rela-
tion between the different variables (gender, site of pneumonia,
presence or absence of respiratory failure, the need for
mechanical ventilation) and the mean of platelet count by
using one way ANOVA test.
Table 3 shows that there was no signiﬁcant statistical corre-
lation between the mean of platelet count versus age and
length of hospital stay by using Spearman correlation.Table 2 Correlation between the mean of platelet count
versus different variables.
Variables Platelets count Mean ± SD t P Sig
Gender
Male 195 ±55 0.2 0.67 NS
Female 202 ±49
Site
Lobar 189 ±80 0.9 0.37 NS
Multilobar 230 ±110
Respiratory failure
Non 221 ±110 1.8 0.17 NS
Type 1 144 ±78
Type 2 219 ±105.5
MV
Positive 185 ±87 0.79 0.33 NS
Negative 215 ±110.9
#one way ANOVA test.Table 4 shows that there was a signiﬁcant statistical relation
between the occurrence of respiratory complications and both
thrombocytopenia and thrombocytosis by using chi-square
test.
Table 5 shows that that there was a signiﬁcant statistical
relation between both thrombocytopenia and thrombocytosis
and the CURB65 score as a score for severity of CAP by using
one way ANOVA test.
Table 6 shows that there was a signiﬁcant statistical relation
between both thrombocytopenia and thrombocytosis and mor-
tality among the patients with CAP by using chi-square test.
Table 7 shows that platelet count is considered better pos-
itive than a negative predictor value to the outcome by using
the receiver operating curve (ROC curve).
Discussion
Clinicians have always evaluated the degree of leucocytosis in
patients with pneumonia as an indication of systemic inﬂam-
matory response and severity of disease. Thrombocytopenia
is also a recognized marker of poor outcomes in patients with
pneumonia, due to the association of low platelet counts with
disseminated intravascular coagulation and severe sepsis [3].
Platelets are important inﬂammatory cells that can undergo
chemotaxis and are able to release numerous pro inﬂammatory
molecules. In patients with CAP, there is an association
between levels of inﬂammatory cytokines and severity of dis-
ease. It can be theorized that thrombocytosis may favor an
exaggerated systemic inﬂammatory response that, in turn, pro-
duces poor outcomes in patients with CAP [7].
This study was a prospective one about the relation
between platelet count abnormality and the severity and out-
come of community-acquired pneumonia cases. The study
included 40 cases of CAP admitted at the Chest Department
and Respiratory ICU at Ain Shams University Hospital, as
well as, the Chest Department and Respiratory ICU at Ain
Shams University Specialized Hospital.
The results showed that 75% of the enrolled patients were
males and 25% were females, the age ranged from 17 to
84 years with a mean of 60 ± 17 years, the length of hospital
stay ranged from 3 to 25 days with a mean of 11.5 ± 5 days,7
patients (17.5%) had thrombocytopenia (platelet count
<150,000), 30 patients (75%) had normal platelet count
(150,000–400,000) and only 3 patients (7.5%) had thrombocy-
tosis (platelet count >400,000), 80% of the patients presented
with lobar consolidation while the other 20% presented with
multilobar consolidation, 50% of the included patients had
type II respiratory failure, 30% had type I respiratory failure,
while only 20% of the patients did not have respiratory failure,
47.5% of the patients did not develop any complications,
30% developed respiratory complications, 17.5% developed
Table 4 Relation between type of platelet count and different complications.
Type of complications Type of platelet count X2 P Sig
Thrombocytopenia Normal platelet count Thrombocytosis
No 2(28.57%) 17(56.67%) 0
Respiratory 5(71.43%) 5(16.66%) 2(66.67%)
Non respiratory 0 6(20.00%) 1(33.33%) 13 0.008 S
Both 0 2(6.67%) 0
Table 5 Relation between type of platelet count and CURB65 score.
Variable Type of platelet count t P Sig
Thrombocytopenia Normal platelet count Thrombocytosis
CURB65 score 4.2 ± 1.5 3 ± 1.3 3.8 ± 1.1 4.2 0.002 S
Table 6 Relation between type of platelet count and outcome.
Variable Type of platelet count X2 P Sig
Thrombocytopenia Normal platelet count Thrombocytosis
Outcome
Alive 2(28.57%) 15(50.0%) 0 4.7 0.05 S
Died 5(71.43%) 15(50.0%) 3(100%)
Table 7 Validity of platelet count versus outcome.
Variables %
Best cut oﬀ = 150,000
Area under the curve 0.56
Sensitivity 70
Speciﬁcity 44
PPV 53
NPV 75
502 A.A. ElMaraghy et al.non-respiratory complications and 5% developed both
respiratory and non-respiratory complications, and ﬁnally,
42.5% of the patients survived while 57.5% of them died.
There was no signiﬁcant relation between the different
variables (gender, site of pneumonia, presence or absence of
respiratory failure, the need for mechanical ventilation) and
the mean of platelet count. Also, there was no signiﬁcant
correlation between the mean of platelet count versus age
and length of hospital stay.
Importantly, there was a signiﬁcant relation between the
occurrence of respiratory complications (the majority was in
the form of acute respiratory distress syndrome) and both
thrombocytopenia and thrombocytosis. Moreover, there was
a signiﬁcant relation between both thrombocytopenia and
thrombocytosis and the CURB65 score as a score for severity
of CAP. These results are similar to those of Martinez et al. [8],
who conducted a 12 month prospective multicenter and longi-
tudinal study in 10 hospitals of a Spanish Mediterranean area.
They included hospitalized adult patients with CAP. They
analyzed 1314 patients. Forty-three patients (3%) presented
with thrombocytopenia, 107 (8%) thrombocytosis and 1164(89%) had normal platelet count. Lower platelet counts were
associated with an increase of severity of disease by PSI or
CURB65. Patients with thrombocytopenia presented more
often with severe sepsis and intensive care unit admission,
whereas those with thrombocytosis presented more frequently
with respiratory complications such as empyema. No associa-
tion was found between abnormal platelet count and increased
risk of mortality in the multivariable logistic regression model.
They concluded that abnormal platelet count is associated with
severity of disease and more frequently complications in
patients with CAP.
On the other hand, the results of the present study showed
that the overall mortality rate among the enrolled patients was
57.5%, among the patients with thrombocytopenia was
71.43%, among the patients with normal platelet count was
50% and among the patients with thrombocytosis was
100%. By deﬁning a platelet count 150,000 as a cut-off point,
the results of our study found that platelet count is considered
better positive than a negative predictor to the outcome. This
partially matches with the results of Georges et al. [9], who
conducted a multicenter retrospective study showing, in 822
patients admitted to an ICU for severe CAP, that severe
thrombocytopenia (<50,000 cells/lL) was an independent
predictor of mortality. They looked at the impact of thrombo-
cytosis in their patients. The overall ICU mortality rate was
35.4%. Thrombocytosis was present in 70 (5.7%) patients.
They did not ﬁnd any difference in outcome compared with
patients with thrombocytosis. When considering the cause of
death according to platelet numbers, they found it was essen-
tially related to sepsis complications in patients with thrombo-
cytopenia (septic refractory shock, n = 18; multi organ
failure, n = 17; ARDS, n = 11; nosocomial pneumonia,
Platelet count as a marker for severity of community acquired pneumonia 503n = 8), while in patients with thrombocytosis, the cause of
death was mostly related to complications of ICU stay or asso-
ciated co morbidity. Thus, they believed that thrombocytope-
nia remains an important predictor of outcome in patients
with severe CAP. In these patients, thrombocytosis is not asso-
ciated with worse outcome. The difference between the results
of our study and those of Georges et al. might be due to the
obvious discrepancy in the number of enrolled patients with
thrombocytosis in both studies. On the contrary, Prina et al.
[10] prospectively analyzed 2423 consecutive, hospitalized
patients with CAP. They found that ﬁfty-three patients (2%)
presented with thrombocytopenia, 204 (8%) with thrombocy-
tosis, and 2166 (90%) had normal platelet counts. Patients
with thrombocytosis presented more frequently with respira-
tory complications, such as complicated pleural effusion and
empyema, whereas those with thrombocytopenia presented
more often with severe sepsis, septic shock, need for invasive
mechanical ventilation and ICU admission. Patients with
thrombocytosis and patients with thrombocytopenia had
longer hospital stays and higher 30-day mortality and readmis-
sion rates than those with normal platelet counts. Multivariate
analysis conﬁrmed a signiﬁcant association between thrombo-
cytosis and 30-day mortality. Adding thrombocytosis to the
confusion, respiratory rate, and BP plus age P65 years score
slightly improved the accuracy to predict mortality (area under
the receiver operating characteristic curve increased from 0.634
to 0.654, P= .049). They concluded that thrombocytosis in
patients with CAP is associated with poor outcome,
complicated pleural effusion, and empyema. The presence of
thrombocytosis in CAP should encourage ruling out respira-
tory complication and could be considered for severity
evaluation.
The results of our study are supported with those of Mir-
saeidi et al. [11], who conducted a retrospective cohort study
of 500 consecutive patients admitted with CAP to the Veterans
Administration Medical Center of Louisville, Kentucky,
between June 2001 and March 2006. This study indicated that
thrombocytopenia and thrombocytosis were signiﬁcantly asso-
ciated with mortality in patients with CAP. At the time of hos-
pitalization, abnormalities in platelet count were better
predictors of clinical outcomes in patients with CAP when
compared with abnormalities in leukocyte count. On the other
hand, when Cunha et al. [12] revised the results of Mirsaeidi
et al., they were not at all convinced that the platelet count
alone is a prognostic indicator in adults hospitalized with sev-
ere CAP. In both pieces, information was lacking regarding
pathogen distribution, a key determinant of the platelet count.
Because thrombocytopenia is not an acute-phase reactant, it
cannot be said that thrombocytopenia with severe CAP is an
indicator of severity and, thereby, is indirectly related to prog-
nosis. Any CAP pathogen may present as severe CAP, depend-
ing on the cardiopulmonary and immune status of the host.
Severity of CAP is largely related to these factors rather than
to pathogen virulence per se. They also stated that if thrombo-
cytopenia is present with bacterial CAP, clinicians should look
for an alternate explanation (e.g., drug induced), or it may
represent a complication (e.g., hemolytic uremic syndrome).
In normal hosts, most CAP pathogens are not associated with
either thrombocytopenia or thrombocytosis. Normal platelet
counts are the rule among typical CAP pathogens, as well as
among atypical CAP pathogens. In the absence of details oncardiopulmonary and humoral immune function as well as
speciﬁc pathogen data, the platelet count is necessarily an
imprecise prognostic indicator. In immunocompetent adults,
it would seem that thrombocytopenia and thrombocytosis,
rather than having a prognostic signiﬁcance, may be more
important diagnostically in suggesting a speciﬁc CAP
pathogen.
Conclusion
A better understanding of the role of platelets in the outcomes
of patients with pneumonia may generate new prognostic and
therapeutic modalities for patients with severe disease.
Recommendations
1. Future research is needed to assess whether abnormality in
platelet counts in patients with CAP is just a marker of the
inﬂammatory response or is in part responsible for
mortality. In particular, future research should focus on
investigating the cause of death for patients with abnormal
platelet counts.
2. Also, future researches should focus on the relation
between platelet count abnormality and the causative
pathogen of CAP.
3. When evaluating a complete blood count report in patients
with CAP, platelet count may be informative for predicting
patient poor outcomes in addition to the commonly used
leukocyte count.References
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